Looks like we have 7 trials with multiple indications ending the first half of this year and 4 more the second half in ZENE. So we should expect some info which might effect ZENE assets and which should indirectly effect RVX. ....Comments appreciated!!!.....Or will our Pharma bed partners in ZENE refuse to publicly announce preliminary results,,will all be a big secret? Will RVX get funding from deals around indications?,,if so, might a full take out be best choice for a buyer of both these compnaies!
CEPC - Pll - Ends 1H 2024
Ovarian - Pl - Ends 1H 2024
Nut Carcinoma - Pl/ll - 1H 2024
PDAC Lymphoma - Pl/lb - 1H 2024
TBNC,CRC - Pl - 1H 2024
Ovarian PDAC - Pll - 1H 2024
CRPC, Breast,NSCLC - Pll - 1H 2024
TNBC - Pl - 1H 2024